EVOTEC SE ADR 1/2 O.N. (EVTA) - Total Assets
Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) holds total assets worth €1.71 Billion EUR (≈ $2.00 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore EVTA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
EVOTEC SE ADR 1/2 O.N. - Total Assets Trend (2021–2025)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s total assets have evolved over time, based on quarterly financial data. See EVOTEC SE ADR 1/2 O.N. shareholders equity for net asset value and shareholders' equity analysis.
EVOTEC SE ADR 1/2 O.N. - Asset Composition Analysis
Current Asset Composition (December 2025)
EVOTEC SE ADR 1/2 O.N.'s total assets of €1.71 Billion consist of 44.5% current assets and 55.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.4% |
| Accounts Receivable | €135.96 Million | 7.9% |
| Inventory | €29.32 Million | 1.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €31.57 Million | 1.8% |
| Goodwill | €272.37 Million | 15.9% |
Asset Composition Trend (2021–2025)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EVTA stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EVOTEC SE ADR 1/2 O.N.'s current assets represent 44.5% of total assets in 2025, a decrease from 49.3% in 2021.
- Cash Position: Cash and equivalents constituted 23.4% of total assets in 2025, down from 31.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 12.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 15.9% of total assets.
EVOTEC SE ADR 1/2 O.N. Competitors by Total Assets
Key competitors of EVOTEC SE ADR 1/2 O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
EVOTEC SE ADR 1/2 O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.07 | 1.98 | 2.09 |
| Quick Ratio | 1.99 | 1.89 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €394.87 Million | €337.38 Million | €364.48 Million |
EVOTEC SE ADR 1/2 O.N. - Advanced Valuation Insights
This section examines the relationship between EVOTEC SE ADR 1/2 O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | -10.4% |
| Total Assets | €1.71 Billion |
| Market Capitalization | $792.54 Million USD |
Valuation Analysis
Below Book Valuation: The market values EVOTEC SE ADR 1/2 O.N.'s assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: EVOTEC SE ADR 1/2 O.N.'s assets decreased by 10.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual total assets of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.71 Billion ≈ $2.00 Billion |
-10.38% |
| 2024-12-31 | €1.91 Billion ≈ $2.24 Billion |
-15.09% |
| 2023-12-31 | €2.25 Billion ≈ $2.63 Billion |
-0.21% |
| 2022-12-31 | €2.26 Billion ≈ $2.64 Billion |
+0.99% |
| 2021-12-31 | €2.24 Billion ≈ $2.61 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more